← Eichor
Condition: Thyroid Associated Ophthalmopathies Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Thyroid Associated Ophthalmopathies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of IBI3031 in Participants With Thyroid Eye Disease
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07622368An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
Phase 2 · 8 location(s) · Amgen · NCT07438405Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Phase N/A · 1 location(s) · Elazıg Fethi Sekin Sehir Hastanesi · NCT07480720Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
NA · 1 location(s) · Peking University Third Hospital · NCT07423013MHB018A Treatment in Patients With Active Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT06989918Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT06590220Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07262476MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07257185A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Phase 1/Phase 2 · 44 location(s) · Amgen · NCT06401044Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
Phase 2 · 1 location(s) · Haukeland University Hospital · NCT04936854Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07547930Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the A
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152366Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152392Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
Phase 3 · 1 location(s) · Janjira Petsuksiri · NCT06392906Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
NA · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07400757The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Phase N/A · 1 location(s) · Walter Reed National Military Medical Center · NCT06275373Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
NA · 1 location(s) · Peking University Third Hospital · NCT06359795Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2/Phase 3 · 2 location(s) · Sling Therapeutics, Inc. · NCT06112340A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07113262A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Phase 3 · 27 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07211776Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NA · 1 location(s) · Sun Yat-sen University · NCT06588764Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Phase N/A · 1 location(s) · Vastra Gotaland Region · NCT05678374Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE Nati
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT07716397A Clinical Study of Cizutamig in Thyroid Eye Disease
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07597200Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
Phase N/A · 1 location(s) · Imperial College London · NCT05012033Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Tr
Phase N/A · 9 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07117981Bimatoprost as a Treatment for Graves' Orbitopathy
EARLY_Phase 1 · 1 location(s) · Johns Hopkins University · NCT03708627The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO
Phase 4 · 2 location(s) · Shanghai Changzheng Hospital · NCT07152340A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06569758A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa
Phase 4 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06927375
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.